Profile: CEL-SCI Corporation (CVM)

CEL-SCI Corporation (CEL-SCI), incorporated on March 22, 1983, is engaged in the business of Multikine cancer therapy; new cold fill manufacturing service to the pharmaceutical industry, and LEAPS technology, with two products: H1N1, a swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted. It is the cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer.

Multikine is a type of immunotherapy in that it is an immunotherapy incorporating both active and passive immune activity. Multikine is designed to target the tumor micro-metastases that are responsible for treatment failure. The Company has completed clinical trials in over 200 patients for Multikine. Multikine is being developed as an adjunct (additive) therapy to the treatment of untreated head and neck cancer patients.

CEL-SCI's T-cell modulation process uses heteroconjugates to direct the body to choose a specific immune response. The heteroconjugate technology, referred to as Ligand Epitope Antigen Presentation System (L.E.A.P.S), is focused to selectively stimulate the human immune system to fight bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer.

Using the LEAPS technology, CEL-SCI has created a peptide treatment for H1N1 (swine flu) hospitalized patients. This L.E.A.P.S. flu treatment is designed to focus on the conserved non-changing epitopes of the different strains of Type A Influenza viruses (H1N1, H5N1, H3N1), including swine, avian or bird, and Spanish Influenza in order to minimize the chance of viral escape by mutations from immune recognition. CEL-SCI's L.E.A.P.S. flu treatment contains epitopes known to be associated with immune protection against influenza in animal models. With its LEAPS technology, CEL-SCI also discovered a second peptide named CEL-2000, a rheumatoid arthritis vaccine.